AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6269192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride infusion
Number of subjects: 0
Study 6269192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30037432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 47
Study 30037432 — intervention group
Group type: COMPARATOR
Intervention: Tumor necrosis factor inhibitors (TNFi)
Number of subjects: 47
Study 29036250 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% topical spray
Number of subjects: 32
Study 29036250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29036250 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray
Number of subjects: 32
Study 25476537 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg orally daily, days 1-3 of every 7-d period) with carboplatin (AUC 2, weekly) and nab-paclitaxel (100 mg/m2 weekly)
Number of subjects: 62
Study 25476537 — intervention group
Group type: COMPARATOR
Intervention: Placebo with carboplatin (AUC 2, weekly) and nab-paclitaxel (100 mg/m2 weekly)
Number of subjects: 62
Study 25476537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (vorinostat and placebo)
Number of subjects: 62
Study 25476537 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in SUL(max) on (18)F-FDG PET
Number of subjects: 62
Study 25476537 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and change in Ki-67
Number of subjects: 62
Study 23117253 — intervention group
Group type: EXPERIMENTAL
Intervention: LORS-Enabled Dialogue (LED) intervention
Number of subjects: 90
Study 23117253 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 21363973 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 0
Study 21363973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookworm infection
Number of subjects: 0
Study 21363973 — intervention group
Group type: EXPERIMENTAL
Intervention: S. haematobium infection
Number of subjects: 0
Study 18645542 — intervention group
Group type: EXPERIMENTAL
Intervention: J‐Tip jet injection of 1% buffered lidocaine
Number of subjects: 70
Study 18645542 — intervention group
Group type: COMPARATOR
Intervention: Topical 4% ELA‐Max
Number of subjects: 70
Study 16585868 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel and cisplatin (25 mg/m cisplatin and 35 mg/m docetaxel once a week for 3 weeks followed by 1 week without treatment)
Number of subjects: 21
Study 16585868 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel and cisplatin
Number of subjects: 21
Study 12650633 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel implants
Number of subjects: 16000
Study 12650633 — intervention group
Group type: COMPARATOR
Intervention: Jadelle
Number of subjects: 16000
Study 11098103 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of morphine (targeted concentration of 20 ng/ml)
Number of subjects: 83
Study 11098103 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus doses of morphine
Number of subjects: 83
Study 1300518 — intervention group
Group type: EXPERIMENTAL
Intervention: Discolored lenses (amber lens discoloration achieved using human‐worn 55% water hydrophilic contact lenses heated in a 1% potassium sorbate, low pH saline solution)
Number of subjects: 15
Study 3895254 — intervention group
Group type: COMPARATOR
Intervention: Lofepramine (140 mg and 210 mg)
Number of subjects: 5
Study 3895254 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (100 mg and 150 mg)
Number of subjects: 5
Study 3895254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 5
Study 31315118 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight participants dividing monetary rewards in the dictator game
Number of subjects: 168
Study 31315118 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight participants with stronger explicit antifat attitudes
Number of subjects: 168
Study 31315118 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit attitudes toward people with obesity
Number of subjects: 168
Study 29725983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 1902
Study 29725983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 1902
Study 29725983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1902
Study 27801404 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological feedback (BFB) technique
Number of subjects: 337
Study 27801404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 337
Study 25493596 — intervention group
Group type: COMPARATOR
Intervention: No chemoprevention
Number of subjects: 186
Study 25493596 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dihydroartemisinin-piperaquine
Number of subjects: 186
Study 25493596 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily trimethoprim-sulfamethoxazole
Number of subjects: 186
Study 25493596 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine-pyrimethamine
Number of subjects: 186
Study 25493596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 186
Study 22314936 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for fracture risk using the FRAX algorithm and DXA assessment.
Number of subjects: 11580
Study 22314936 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 11580
Study 20379614 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg NRT
Number of subjects: 479
Study 20379614 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 mg NRT
Number of subjects: 479
Study 20379614 — intervention group
Group type: COMPARATOR
Intervention: NRT (both doses)
Number of subjects: 479
Study 18339044 — intervention group
Group type: EXPERIMENTAL
Intervention: +2DS blur over the dominant eye
Number of subjects: 14
Study 18339044 — intervention group
Group type: EXPERIMENTAL
Intervention: +2DS blur over the non-dominant eye
Number of subjects: 14
Study 18339044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant eye occluded
Number of subjects: 14
Study 18339044 — intervention group
Group type: COMPARATOR
Intervention: Binocular vision
Number of subjects: 14
Study 15844708 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a plus ribavirin (180 microg peg‐interferon alpha‐2a + 800-1000 mg/day ribavirin)
Number of subjects: 124
Study 15844708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin and amantadine (800-1000 mg/day ribavirin + 200 mg/day amantadine)
Number of subjects: 124
Study 15844708 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a plus mycophenolate mofetil (180 microg peg‐interferon alpha‐2a + 2 g/day mycophenolate mofetil)
Number of subjects: 124
Study 15844708 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg/day)
Number of subjects: 124
Study 14501100 — intervention group
Group type: EXPERIMENTAL
Intervention: strategy group (received training on methods for remembering picture groupings)
Number of subjects: 24
Study 14501100 — intervention group
Group type: COMPARATOR
Intervention: control group (received no training)
Number of subjects: 24
Study 14501100 — intervention group
Group type: EXPERIMENTAL
Intervention: strategy group
Number of subjects: 24
Study 11829803 — intervention group
Group type: EXPERIMENTAL
Intervention: Short veno-venous hemofiltration (SVVH, 4hr)
Number of subjects: 20
Study 11829803 — intervention group
Group type: COMPARATOR
Intervention: Non-hemofiltration group (NHF)
Number of subjects: 20
Study 8644661 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 2.5 to 5 mg twice daily
Number of subjects: 0
Study 8644661 — intervention group
Group type: COMPARATOR
Intervention: Enalapril and loop diuretics with or without digoxin
Number of subjects: 0
Study 1728688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 gm before operation and 750 mg every 3 hours during operation)
Number of subjects: 559
Study 1728688 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1 gm before operation and 500 mg every 4 hours during operation)
Number of subjects: 559
Study 1728688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 559
Study 1728688 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 559
Study 6741802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 to 50 mg)
Number of subjects: 15
Study 6741802 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (5 to 30 mg)
Number of subjects: 15
Study 31521257 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior vena cava (IVC) filters
Number of subjects: 0
Study 31521257 — intervention group
Group type: COMPARATOR
Intervention: IVC filters
Number of subjects: 0
Study 30071416 — intervention group
Group type: EXPERIMENTAL
Intervention: dTMS combined with SSRIs
Number of subjects: 34
Study 30071416 — intervention group
Group type: COMPARATOR
Intervention: sham dTMS
Number of subjects: 34
Study 27310980 — intervention group
Group type: EXPERIMENTAL
Intervention: He electroacupuncture
Number of subjects: 448
Study 27310980 — intervention group
Group type: EXPERIMENTAL
Intervention: Shu-Mu electroacupuncture
Number of subjects: 448
Study 27310980 — intervention group
Group type: EXPERIMENTAL
Intervention: He-Shu-Mu electroacupuncture
Number of subjects: 448
Study 27310980 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 448
Study 27310980 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (all groups combined)
Number of subjects: 448
Study 24586404 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning-type group in the morning session
Number of subjects: 0
Study 24586404 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning-type group in the evening session
Number of subjects: 0
Study 24586404 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-type group in the morning session
Number of subjects: 0
Study 24586404 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-type group in the evening session
Number of subjects: 0
Study 22925169 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion control diet
Number of subjects: 157
Study 22925169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy density diet
Number of subjects: 157
Study 22925169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 157
Study 22925169 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 157
Study 20395917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-conjunctival injection of dexamethasone and gentamicin combination (Group A)
Number of subjects: 60
Study 20395917 — intervention group
Group type: COMPARATOR
Intervention: 5% povidone-iodine drop (Group B)
Number of subjects: 60
Study 17504616 — intervention group
Group type: EXPERIMENTAL
Intervention: Physio-psychological treatment
Number of subjects: 178
Study 17504616 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (DDAVP tablets)
Number of subjects: 178
Study 17504616 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (physio-psychological + drug treatment)
Number of subjects: 178
Study 17504616 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study 16521533 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic examination in preterm neonates
Number of subjects: 143
Study 16521533 — intervention group
Group type: COMPARATOR
Intervention: Control group of 31 children from term deliveries
Number of subjects: 143
Study 11961326 — intervention group
Group type: EXPERIMENTAL
Intervention: Remineralization without fluoride (Group B)
Number of subjects: 4
Study 11961326 — intervention group
Group type: EXPERIMENTAL
Intervention: Remineralization with 1 ppm fluoride (Group C)
Number of subjects: 4
Study 11961326 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural incipient lesions (Group D)
Number of subjects: 4
Study 11961326 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 4
Study 10409589 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 x 1-mg capsules)
Number of subjects: 9
Study 10409589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules)
Number of subjects: 9
Study 7556743 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide Novel Ophthalmic Delivery System (NODS) and guttae phenylephrine 10% applied once, 2 hours before surgery
Number of subjects: 0
Study 7556743 — intervention group
Group type: COMPARATOR
Intervention: Standard pre-operative regime of guttae cyclopentolate 1% and guttae phenylephrine 10% used four times before surgery
Number of subjects: 0
Study 2062626 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb strain measles vaccine (high dose)
Number of subjects: 2097
Study 2062626 — intervention group
Group type: COMPARATOR
Intervention: Schwarz strain measles vaccine (control)
Number of subjects: 2097
Study 6628523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pindolol
Number of subjects: 6
Study 6628523 — intervention group
Group type: COMPARATOR
Intervention: i.v. pindolol
Number of subjects: 6
Study 31063192 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of antiretroviral therapy
Number of subjects: 0
Study 31063192 — intervention group
Group type: COMPARATOR
Intervention: Deferred initiation of antiretroviral therapy
Number of subjects: 0
Study 30024203 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday Matters program
Number of subjects: 31
Study 30024203 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 31
Study 27103111 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive induction of labor at 37-39 weeks
Number of subjects: 200000
Study 27103111 — intervention group
Group type: COMPARATOR
Intervention: Ongoing pregnancy (expectant management)
Number of subjects: 200000
Study 25469046 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoyao pill
Number of subjects: 180
Study 25469046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 22302316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular betamethasone injections (28 mg, up to four swollen joints/visit)
Number of subjects: 160
Study 22302316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular betamethasone injections
Number of subjects: 160
Study 19398575 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin/platinum/fluoropyrimidine combination chemotherapy (ECF, ECX, EOF, EOX) with 1 mg of warfarin for thromboprophylaxis
Number of subjects: 964
Study 19398575 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin/platinum/fluoropyrimidine combination chemotherapy (EOF/EOX)
Number of subjects: 964
Study 19398575 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin/platinum/fluoropyrimidine combination chemotherapy (F group)
Number of subjects: 964
Study 19398575 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin/platinum/fluoropyrimidine combination chemotherapy (ECF/EOF arms)
Number of subjects: 964
Study 19398575 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin/platinum/fluoropyrimidine combination chemotherapy
Number of subjects: 964
Study 17234730 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose RRR-alpha-tocopherol (1200 IU/day for 2 years)
Number of subjects: 127
Study 17234730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 16314551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 47
Study 16314551 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene (SH) instructions
Number of subjects: 47
Study 16314551 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 47
Study 12494125 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart fatty acid binding protein (FABP)
Number of subjects: 57
Study 12494125 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I (TnI)
Number of subjects: 57
Study 12494125 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine kinase (CK)
Number of subjects: 57
Study 10219658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% HA in phosphate buffered saline (PBS)
Number of subjects: 26
Study 10219658 — intervention group
Group type: COMPARATOR
Intervention: 0.01% HA in PBS (Control)
Number of subjects: 26
Study 8580883 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 47
Study 8580883 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 47
Study 8580883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2131864 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO group)
Number of subjects: 20
Study 2131864 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP group)
Number of subjects: 20
Study 6996618 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 0.05% fluocinonide in an adhesive base
Number of subjects: 89
Study 30535396 — intervention group
Group type: EXPERIMENTAL
Intervention: Group prenatal care (CenteringPregnancy model)
Number of subjects: 129
Study 30535396 — intervention group
Group type: COMPARATOR
Intervention: Traditional one-on-one prenatal care
Number of subjects: 129
Study 28039583 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g D-chiro-inositol plus 400 mcg folic acid once daily
Number of subjects: 26
Study 28039583 — intervention group
Group type: COMPARATOR
Intervention: 400 mcg folic acid only once daily
Number of subjects: 26
Study 25450134 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted home exercise program
Number of subjects: 63
Study 25450134 — intervention group
Group type: COMPARATOR
Intervention: Conservative home-training following printed instructions
Number of subjects: 63
Study 23750773 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping plans made to deal with personal smoking related risk situations
Number of subjects: 563
Study 22773240 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide long-acting repeatable depot (OctLAR), maximum dose 40 mg, administered for 2 years (Year 1 and Year 2).
Number of subjects: 42
Study 22773240 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide long-acting repeatable depot (OctLAR), administered for 2 years (Year 1 and Year 2).
Number of subjects: 42
Study 22773240 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide long-acting repeatable depot (OctLAR), pooled analyses of all individuals who received OctLAR for 12 months.
Number of subjects: 42
Study 22773240 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (Year 1), crossed over to OctLAR in Year 2.
Number of subjects: 42
Study 19682194 — intervention group
Group type: EXPERIMENTAL
Intervention: p.o. omeprazole 80 mg bolus followed by 40 mg every 12 h for 72 h
Number of subjects: 90
Study 19682194 — intervention group
Group type: COMPARATOR
Intervention: i.v. omeprazole 80 mg followed by infusion 8 mg/h for 72 h
Number of subjects: 90
Study 19682194 — intervention group
Group type: EXPERIMENTAL
Intervention: p.o. pantoprazole 80 mg bolus followed by 80 mg every 12 h for 72 h
Number of subjects: 90
Study 19682194 — intervention group
Group type: COMPARATOR
Intervention: i.v. pantoprazole 80 mg followed by infusion 8 mg/h for 72 h
Number of subjects: 90
Study 19682194 — intervention group
Group type: EXPERIMENTAL
Intervention: p.o. rabeprazole 80 mg bolus followed by 40 mg every 12 h for 72 h
Number of subjects: 90
Study 19682194 — intervention group
Group type: COMPARATOR
Intervention: i.v. rabeprazole 80 mg followed by infusion 8 mg/h for 72 h
Number of subjects: 90
Study 19682194 — intervention group
Group type: COMPARATOR
Intervention: No proton pump inhibitor treatment
Number of subjects: 90
Study 17261396 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel for 180 days
Number of subjects: 1004
Study 17261396 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel for 30 days
Number of subjects: 1004
Study 15371861 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline filled testicular prosthesis
Number of subjects: 149
Study 11592359 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg CII
Number of subjects: 55
Study 11592359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11592359 — intervention group
Group type: COMPARATOR
Intervention: 0.05 mg CII
Number of subjects: 55
Study 11592359 — intervention group
Group type: COMPARATOR
Intervention: 5 mg CII
Number of subjects: 55
Study 10346406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose (50 ml of 50% glucose)
Number of subjects: 14
Study 10346406 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular glucagon (1 mg)
Number of subjects: 14
Study 7988951 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated image analysis method for evaluating platelet interactions with ECM-coated coverslips
Number of subjects: 0
Study 7988951 — intervention group
Group type: COMPARATOR
Intervention: Standard morphometric procedures
Number of subjects: 0
Study 3183692 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary lacrimal duct occlusion
Number of subjects: 11
Study 3183692 — intervention group
Group type: COMPARATOR
Intervention: Sham occlusion
Number of subjects: 11
Study 4213814 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper bearing device
Number of subjects: 155
Study 4213814 — intervention group
Group type: COMPARATOR
Intervention: Conventional type device
Number of subjects: 155
Study 31240722 — intervention group
Group type: EXPERIMENTAL
Intervention: NDP-led care
Number of subjects: 11281
Study 31240722 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11281
Study 31240722 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus
Number of subjects: 11281
Study 28122530 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA/VILI
Number of subjects: 3086
Study 28122530 — intervention group
Group type: COMPARATOR
Intervention: TCT
Number of subjects: 3086
Study 28122530 — intervention group
Group type: COMPARATOR
Intervention: HPV test
Number of subjects: 3086
Study 25198401 — intervention group
Group type: EXPERIMENTAL
Intervention: Current perception threshold (CPT) measurement combined with stinging test using 50 μL 10% lactic acid
Number of subjects: 0